Shah P, Trostmann U, Tack K
Klinikum der Johann Wolfgang Goethe, Universität Frankfurt am Main, Zentrum der Inneren Medizin, Medizinische Klinik III, Schwerpunkt Infektiologie, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany.
Int J Antimicrob Agents. 2002 Mar;19(3):245-8. doi: 10.1016/s0924-8579(02)00006-7.
In an open-label emergency-use study, 23 patients with bacterial infections caused by multiply drug resistant pathogens were treated with clinafloxacin. Efficacy and safety were evaluated by tabulating investigators' assessments at the end of treatment, treatment discontinuations and adverse event data. Most of the patients were seriously ill and had multi-organ infections, primarily respiratory tract infections such as nosocomial pneumonia and gastrointestinal infections. Eleven patients were successfully treated, two had treatment failure and 10 were not evaluable because the patients died of their underlying disease. Considering that most of the patients had several infections caused by multiply resistant pathogens, clinafloxacin may be useful for the treatment of such life-threatening episodes.
在一项开放标签的紧急使用研究中，23名由多重耐药病原体引起细菌感染的患者接受了克林沙星治疗。通过汇总研究者在治疗结束时的评估、治疗中断情况和不良事件数据来评估疗效和安全性。大多数患者病情严重，患有多器官感染，主要是呼吸道感染，如医院获得性肺炎和胃肠道感染。11名患者得到成功治疗，2名治疗失败，10名患者无法评估，因为这些患者死于基础疾病。考虑到大多数患者有几种由多重耐药病原体引起的感染，克林沙星可能对治疗此类危及生命的情况有用。
